JP2015522032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522032A5 JP2015522032A5 JP2015520594A JP2015520594A JP2015522032A5 JP 2015522032 A5 JP2015522032 A5 JP 2015522032A5 JP 2015520594 A JP2015520594 A JP 2015520594A JP 2015520594 A JP2015520594 A JP 2015520594A JP 2015522032 A5 JP2015522032 A5 JP 2015522032A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- substituted
- here
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000003342 alkenyl group Chemical group 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 206010063837 Reperfusion injury Diseases 0.000 claims 10
- 229940122454 Protein phosphatase 2A inhibitor Drugs 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 230000000451 tissue damage Effects 0.000 claims 5
- 231100000827 tissue damage Toxicity 0.000 claims 5
- 208000028867 ischemia Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 101150024228 mdm2 gene Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666535P | 2012-06-29 | 2012-06-29 | |
| US61/666,535 | 2012-06-29 | ||
| US201361782894P | 2013-03-14 | 2013-03-14 | |
| US61/782,894 | 2013-03-14 | ||
| PCT/US2013/048697 WO2014005080A1 (en) | 2012-06-29 | 2013-06-28 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206285A Division JP2018048178A (ja) | 2012-06-29 | 2017-10-25 | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522032A JP2015522032A (ja) | 2015-08-03 |
| JP2015522032A5 true JP2015522032A5 (enExample) | 2016-08-18 |
| JP6262225B2 JP6262225B2 (ja) | 2018-01-17 |
Family
ID=49783920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520594A Expired - Fee Related JP6262225B2 (ja) | 2012-06-29 | 2013-06-28 | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 |
| JP2017206285A Pending JP2018048178A (ja) | 2012-06-29 | 2017-10-25 | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206285A Pending JP2018048178A (ja) | 2012-06-29 | 2017-10-25 | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150174123A1 (enExample) |
| EP (1) | EP2870161B1 (enExample) |
| JP (2) | JP6262225B2 (enExample) |
| CN (1) | CN104619710B (enExample) |
| CA (1) | CA2876703A1 (enExample) |
| WO (1) | WO2014005080A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| EP2867239A4 (en) | 2012-06-29 | 2015-12-23 | Lixte Biotechnology Inc | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES |
| KR20160004299A (ko) * | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| HRP20241236T1 (hr) | 2014-05-13 | 2024-12-06 | Novartis Ag | Spojevi i pripravci za induciranje hondrogeneze |
| WO2016014778A1 (en) | 2014-07-24 | 2016-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
| US20160074390A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
| MX382044B (es) * | 2015-02-19 | 2025-03-13 | Lixte Biotechnology Inc | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. |
| JP7187023B6 (ja) | 2015-05-15 | 2023-01-05 | リクスト・バイオテクノロジー，インコーポレイテッド | オキサビシクロヘプタンプロドラッグ |
| AU2017370731B2 (en) * | 2016-12-08 | 2022-06-02 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
| EP3773571A1 (en) | 2018-03-28 | 2021-02-17 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
| CN118791500B (zh) * | 2024-06-17 | 2025-11-21 | 中国药科大学 | 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931460A (en) * | 1987-09-17 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Post-ischemic myocardial dysfunction using thromboxane A2 antagonists |
| WO1998014606A1 (en) * | 1996-10-04 | 1998-04-09 | South Alabama Medical Science Foundation | Method for diminishing myocardial infarction using protein phosphatase inhibitors |
| BRPI0806365B8 (pt) | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
| WO2010014141A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| KR20160004299A (ko) * | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| US20160074390A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2013
- 2013-06-28 WO PCT/US2013/048697 patent/WO2014005080A1/en not_active Ceased
- 2013-06-28 JP JP2015520594A patent/JP6262225B2/ja not_active Expired - Fee Related
- 2013-06-28 CN CN201380035527.1A patent/CN104619710B/zh not_active Expired - Fee Related
- 2013-06-28 EP EP13808660.8A patent/EP2870161B1/en not_active Not-in-force
- 2013-06-28 CA CA2876703A patent/CA2876703A1/en not_active Abandoned
- 2013-06-28 US US14/408,208 patent/US20150174123A1/en not_active Abandoned
-
2017
- 2017-10-25 JP JP2017206285A patent/JP2018048178A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| SI2820009T1 (en) | Serine / Threonine kinase inhibitors | |
| JP2016505614A5 (enExample) | ||
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2016503797A5 (enExample) | ||
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2015536947A5 (enExample) | ||
| JP2013518050A5 (enExample) | ||
| EA201400232A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения | |
| JP2012184234A5 (enExample) | ||
| EA201290632A1 (ru) | Производные бетулина | |
| JP2013537203A5 (enExample) | ||
| JP2016532667A5 (enExample) | ||
| JP2019501130A5 (enExample) | ||
| RU2015106730A (ru) | Фармацевтическая или косметическая композиция для лечения алопеции | |
| EA201391288A1 (ru) | Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз | |
| EA201000104A1 (ru) | Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний | |
| JP2015522650A5 (enExample) | ||
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| JP2017520528A5 (enExample) | ||
| JP2008508287A5 (enExample) |